Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 8/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 8/20 | 0.74 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.74 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.74 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.74 |
| ▸ | ESR1 | P03372 | 1/20 | 0.74 |
| ▸ | PGR | P06401 | 1/20 | 0.74 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.74 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.74 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.74 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.74 |
| ▸ | DRD1 | P21728 | 1/20 | 0.74 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.74 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.74 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.74 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.74 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14930683 | 0.89 | CYP2C9 (0.77) | CYP2C9CYP2C19KCNH2CYP2D6CYP3A4 | |
| SCHEMBL19236401 | 0.89 | CYP2C9 (0.77) | CYP2C9CYP2C19KCNH2CYP2D6CYP3A4 | |
| SCHEMBL639662 | 0.88 | CYP2C9 (0.75) | CYP2C9CYP2C19KCNH2CYP2D6CYP3A4 | |
| SCHEMBL1183658 | 0.86 | CYP2C9 (0.81) | CYP2C9CYP2C19KCNH2CYP2D6CYP3A4 | |
| SCHEMBL5342750 | 0.85 | CYP2C9 (0.74) | CYP2C9CYP2C19KCNH2CYP2D6CYP3A4 | |
| Etravirine SCHEMBL52691 | 0.85 | CYP2C9 (1.00) | CYP2C9CYP2C19KCNH2CYP2D6CYP3A4 | |
| SCHEMBL14369715 | 0.84 | CYP2C9 (0.72) | CYP2C9CYP2C19KCNH2CYP2D6CYP3A4 | |
| Etravirine SCHEMBL3219153 | 0.84 | CYP2C9 (0.98) | CYP2C9CYP2C19KCNH2CYP2D6CYP3A4 | |
| SCHEMBL247490 | 0.84 | CYP2C9 (0.78) | CYP2C9CYP2C19KCNH2CYP2D6CYP3A4 | |
| Etravirine SCHEMBL28640238 | 0.84 | CYP2C9 (0.98) | CYP2C9CYP2C19KCNH2CYP2D6CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1282607-B1 | PRODRUGS OF HIV REPLICATION INHIBITING PYRIMIDINES | JANSSEN PHARMACEUTICA NV (BE) | 2015-11-11 | — | — | EP | disclosed |
| US-8530655-B2 | HIV replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA NV (BE) | 2013-09-10 | — | — | US | disclosed |
| US-20110263625-A1 | HIV REPLICATION INHIBITING PYRIMIDINES | CORTE BART DE | 2011-10-27 | — | — | US | disclosed |
| US-8003789-B2 | HIV replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA, N.V. (BE) | 2011-08-23 | — | — | US | disclosed |
| US-7763631-B2 | Prodrugs of HIV replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA NV (BE) | 2010-07-27 | — | — | US | disclosed |
| US-20100172970-A1 | ANTIVIRAL COMPOSITIONS | VERRECK GEERT | 2010-07-08 | — | — | US | disclosed |
| EP-1270560-B1 | Hiv replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA NV (BE) | 2010-01-13 | — | — | EP | disclosed |
| US-20080176880-A1 | Activity against strains having acquired resistance nonnucleoside reverse transcriptase inhibitors; human alpha1 acid glycoprotein nonbinding; such as 4-[[(5-bromo-4,6-dichloro)-2-pyrimidinyl]amino]-benzonitrile | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-07-24 | — | — | US | disclosed |
| US-20070196478-A1 | ANTIVIRAL COMPOSITIONS | VERRECK GEERT | 2007-08-23 | — | — | US | disclosed |
| US-7241458-B1 | Antiviral compositions | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-10 | — | — | US | disclosed |
| US-6878717-B2 | HIV replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-04-12 | — | — | US | disclosed |
| US-20040039005-A1 | Nitrogen compounds such as 4-((4-amino-5-bromo-6-(4-cyano-2,6-dimethylphenyloxy)-2 -pyrimidinyl)amino)benzonitrile, used as protease inhibitors for prophylaxis of viral diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-02-26 | — | — | US | disclosed |
| US-20030186990-A1 | Prodrugs of hiv replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA, INC. | 2003-10-02 | — | — | US | disclosed |
| US-20030114472-A1 | Viricides | JANSSEN PHARMACEUTICA, N.V. (BE) | 2003-06-19 | — | — | US | disclosed |
| EP-1002795-B1 | HIV Replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA NV (BE) | 2003-03-05 | — | — | EP | disclosed |
| EP-1270560-A1 | Hiv replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-01-02 | — | — | EP | disclosed |
| EP-1225874-A1 | ANTIVIRAL COMPOSITIONS | Janssen Pharmaceutica N.V. (BE) | 2002-07-31 | — | — | EP | disclosed |
| WO-2001022938-A1 | ANTIVIRAL COMPOSITIONS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-04-05 | — | — | WO | disclosed |
| EP-1002795-A1 | HIV Replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-05-24 | — | — | EP | disclosed |
| WO-2000027825-A1 | HIV REPLICATION INHIBITING PYRIMIDINES | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070196478-A1 | ANTIVIRAL COMPOSITIONS | EIF2AK2, ZC3HAV1, RPL35 | CYP2C9 2076/4885CYP2C19 1690/4885KCNH2 4091/4885 |
| US-20080176880-A1 | Activity against strains having acquired resistance nonnucleoside reverse transcriptase inhibitors; human alpha1 acid glycoprotein nonbinding; such as 4-[[(5-bromo-4,6-dichloro)-2-pyrimidinyl]amino]-benzonitrile | ABCC1, MGAT1, RRM2 | CYP2C9 1440/4885CYP2C19 1598/4885KCNH2 1795/4885 |
| US-20030114472-A1 | Viricides | ZC3HAV1, ZC3HAV1L, POLR2H | CYP2C9 1103/4885CYP2C19 2432/4885KCNH2 328/4885 |
| US-20110263625-A1 | HIV REPLICATION INHIBITING PYRIMIDINES | NSUN2, CCNO, POLR2H | CYP2C9 778/4885CYP2C19 783/4885KCNH2 1658/4885 |
| US-20030186990-A1 | Prodrugs of hiv replication inhibiting pyrimidines | CYP2S1, REV1, CYP1B1 | CYP2C9 229/4885CYP2C19 237/4885KCNH2 4045/4885 |
| US-20100172970-A1 | ANTIVIRAL COMPOSITIONS | EIF2AK2, ZC3HAV1, RPL35 | CYP2C9 2076/4885CYP2C19 1690/4885KCNH2 4091/4885 |
| US-20040039005-A1 | Nitrogen compounds such as 4-((4-amino-5-bromo-6-(4-cyano-2,6-dimethylphenyloxy)-2 -pyrimidinyl)amino)benzonitrile, used as protease inhibitors for prophylaxis of viral diseases | CPN1, CTRL, HPN | CYP2C9 1966/4885CYP2C19 2829/4885KCNH2 1433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.